Cargando…

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is inadequate. Autologous stem cell transplantation is a relatively effective treatment, but residual malignant sites may cause relapse. Allogeneic transplantation may result in durable responses due to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Danylesko, Ivetta, Beider, Katia, Shimoni, Avichai, Nagler, Arnon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357929/ https://www.ncbi.nlm.nih.gov/pubmed/22649466 http://dx.doi.org/10.1155/2012/753407

Ejemplares similares

Characterization of Cyclin E Expression in Multiple Myeloma and Its Functional Role in Seliciclib-Induced Apoptotic Cell Death
por: Josefsberg Ben-Yehoshua, Liat, et al.
Publicado: (2012)

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
por: Beider, Katia, et al.
Publicado: (2022)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
por: Magen, Hila, et al.
Publicado: (2023)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response
por: Beider, Katia, et al.
Publicado: (2020)

Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease
por: Beider, Katia, et al.
Publicado: (2017)

The HPSE Gene Insulator—A Novel Regulatory Element That Affects Heparanase Expression, Stem Cell Mobilization, and the Risk of Acute Graft versus Host Disease
por: Ostrovsky, Olga, et al.
Publicado: (2021)

CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34(+) Cell Mobilization
por: Ostrovsky, Olga, et al.
Publicado: (2021)

P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
por: Geva, Mika, et al.
Publicado: (2023)

Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies
por: Ostrovsky, Olga, et al.
Publicado: (2018)

Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis
por: Eshel, Adi, et al.
Publicado: (2022)

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia
por: Varda-Bloom, Nira, et al.
Publicado: (2016)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

P854: EFFECT OF HPSE AND HPSE2 SNPS ON THE RISK OF DEVELOPING PRIMARY PARASKELETAL MULTIPLE MYELOMA
por: Ostrovsky, Olga, et al.
Publicado: (2023)

Regulatory T Cells in Allogeneic Stem Cell Transplantation
por: Michael, Maria, et al.
Publicado: (2013)

Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma
por: Ostrovsky, Olga, et al.
Publicado: (2023)

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype
por: Beider, Katia, et al.
Publicado: (2014)

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions
por: Yan, Zhi-Ling, et al.
Publicado: (2022)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
por: Beider, Katia, et al.
Publicado: (2022)

Immunotherapy Strategies Against Multiple Myeloma
por: Ma, Jing, et al.
Publicado: (2017)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
por: Abramson, Hanley N.
Publicado: (2023)

Future Directions in Maintenance Therapy in Multiple Myeloma
por: Holstein, Sarah A., et al.
Publicado: (2021)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Immunotherapy for the treatment of multiple myeloma
por: Boussi, Leora S., et al.
Publicado: (2022)

Novel immunotherapies in multiple myeloma – chances and challenges
por: Rasche, Leo, et al.
Publicado: (2021)

Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy
por: Russell, Brian M., et al.
Publicado: (2023)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study
por: Shouval, Roni, et al.
Publicado: (2016)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jir55jonobajikrvsg6gpehkms